Mindreader Biotech (@MindreaderBio) header
Mindreader Biotech (@MindreaderBio) profile picture

PhD (molecular biology) + MD Bridging Science and the Markets in Biotechnology

New York, NY
Joined October 2025
Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)Photo by Mindreader Biotech (@MindreaderBio)
Mindreader Biotech retweeted
448 days since my last pitch ($ABVX), it’s now finally time for my next one: $ZURA (Zura Bio). Like with the $NKTR and $ABVX pitches before this, I will post a general outline of my research on $ZURA as a thread here. However, for those looking to really get into the weeds, there is a Google Doc link to the full length pitch attached below. Let’s dig in. docs.google.com/document/d/1…
63
53
38
605
259,041
American patients lose access when the first trials of a new drug leave the country. They measure the wait in months. The @FDA has started to close that gap with Operation TrialBlazer and tougher scrutiny of foreign data. In @BioSpace today I lay out the next practical steps: a faster path into selected first-in-human studies, priority for sponsors who run pivotal trials & manufacturing here, & a narrow way to stop applications built on stolen IP. Patients should not have to go overseas to try an experimental medicine. Link in comment below 👇 @FDA_KyleD @PeterKolchinsky @t_lorriman @zachscheiner @jrkelly @ArmstrongDrew @maxonwifi @Gardner_LM @rachelcohrs @l_e_whyte @Elijahjstacy
16
22
3
107
4,513
Congratulations to Karim Mikhail on his appointment as Director of CBER. I read his post carefully. One line belongs at the front of every review: “The scientific record tells you what a therapy does. It cannot tell you what waiting for the treatment costs.” I have sat with families whose disease has no approved treatment. For them a review clock is far more than a metric. It is time they may not have. He is right to put that sentence first. It decides how the rest of the job gets done. Every regulatory decision carries two risks: the risk of approving a product, and the risk of not approving it. Both are real. Both land on real people. Only one of them makes headlines. It is easy to say no when you fear tomorrow’s story about a side effect. We will never see the headline about the child who died, the patient who went blind, or the parent who ran out of time because a promising therapy never reached them. For rare and fatal diseases with no other hope, that silence is not neutrality. It is a cost. This is not an argument for lowering the bar. The FDA must still keep products off the market that carry real risk and offer no meaningful benefit. Inspections matter. Data integrity matters. Informed consent matters. Post-approval commitments and rigorous safety monitoring are how you give desperate patients a chance without abandoning the scientific method. Rigor and urgency are not opposites. Rigor is what makes speed worth anything. Speed without rigor is recklessness. Rigor that ignores the patient running out of time is a quieter failure — easier to defend in a memo, and just as final for the family. Where traditional gold-standard trials cannot be done — too few patients, too rapid a decline, a first-in-class mechanism that will never fill a conventional control arm — the honest answer is not “come back in ten years.” Use the best evidence that can actually be generated. Put the uncertainty in plain language. Require the monitoring that protects the next patient. Then trust American physicians and American patients to decide. The FDA’s job is to make sure the science is sound and the information is complete. Then let patients and doctors do what is best for them. The FDA’s only client is the American patient. Full stop. That is why Advisory Committees matter. Open them. Staff them with people who actually treat the disease. Disclose conflicts out loud, under penalty of perjury, before another word is spoken. Give complex science more than a truncated day. Let patients speak. A modest functional gain that looks unimpressive on a slide can be the difference between a life lived and a life lost. I have enormous respect for the career scientists inside CBER (I have gotten to know many including at other FDA centers) The work on both sides of the desk is harder than the other side believes. Leadership’s job is to give them a north star that is patient-first, America-first, and innovation-first at the same time — and then to have their backs when they apply it honestly. “Frontier science only matters when it reaches patients.” Congratulations to Karim. The families who do not have ten years need CBER to get this right. Weigh both risks. Tell the truth about uncertainty. Protect people from empty products. Do not protect process at the expense of the only person the agency exists to serve.
While risk-benefit analysis is essential, for many serious diseases we also need risk-vs-risk analysis: The risk of approving a therapy… versus the risk of not approving it. It’s easy to say “no” when you fear tomorrow’s headlines about a tragic side effect. We will never see headlines about the patient who died because the drug that could have saved them never reached them. Let’s keep our focus on patients — not just p-values. ❤️
13
29
9
149
31,219
Mindreader Biotech retweeted
We are on the cusp of a wave of new therapies for some of the worst diseases. But the world won’t benefit unless the US fixes its drug regulatory system. My new essay for @nytimes, on how slow clinical trials are now the biggest obstacle to curing cancer. nytimes.com/2026/09/04/opini… - I interviewed dozens of researchers, especially oncologists at leading U.S. centers. A striking consensus emerged: science is no longer the main bottleneck to new cancer drugs. It is our ability to test discoveries in patients through clinical trials. - The cost of starting a Phase 1 trial in America has roughly doubled over the past decade. As a result, companies increasingly take early trials abroad: Australia’s Phase 1 trial volume has nearly doubled in a decade, driven mainly by U.S. companies. - Unfortunately, the underlying incentives are badly asymmetric: Institutions can be blamed for harms caused by moving too fast, but almost no one is blamed when patients deteriorate during avoidable delays. One doctor called the emerging system “ritualized safety over actual risk assessment.” Or as, @DavidHongMD put it: "We often forget that the biggest risk is the cancer itself." - This problem is becoming more urgent because medicine itself is changing. Sequencing, biological engineering and A.I. make increasingly personalized therapies possible. But our regulatory system was mostly built for standardized drugs tested in large populations. - @sytse, the co-founder of GitLab, shows what personalized medicine can achieve: after relapsed osteosarcoma and being told there were no options left, he pursued a highly individualized approach and has now been cancer-free for a year. But doing so required extraordinary resources and regulatory expertise. - Pierce Ogden’s father was less lucky. After molecular analysis identified a drug that might target his glioblastoma, the manufacturer agreed to provide it. But administrative barriers delayed access until it was too late. “My dad was ready to try anything,” Pierce told me. “But the system is paternalistic.” - The A.I. revolution is making this bottleneck more important, not less. A.I. relies on relevant data. Information from early-stage trials could compound with A.I. tools to achieve truly revolutionary medicines. Without the data, this is far less likely to happen. - Another important shift is that innovation increasingly comes from academic labs and small biotech companies rather than Big Pharma. These small companies find it far harder to unable to absorb delays and regulatory barriers. - Apart from cancer, China is the biggest winner from America's outdated medical regulations. China has a much faster trial system, with testing often starting a full year earlier. This allows Chinese pharmaceutical companies to experiment and improve medicines while American companies play with mice. Today, half of all drugs licensed by major pharmaceutical companies originate there, up from less than 5 percent only a decade ago. - But we don't need to copy China. The best model is Australia: lots of on-site scientific and ethics reviews, and requirements that are proportionate to small, early-stage trials. Phase 1 studies there begin roughly 6–12 months faster, without any notable increases in adverse safety events. - Operation TrialBlazer, a 2026 HHS initiative is a good start in this direction, but we need legislative action by Congress to truly make Phase I trials faster and more efficient! I want to thank everyone who helped me with this article: everyone I interviewed and the amazing editors at the Times. This is the result of a months long journey of extensive interviews and research. Special thanks go to those who came on the record. One of the features of the system is an atmosphere of fear, where practitioners are afraid to publicly come out and explain these issues. So anyone who does is a hero in my book!
82
415
74
1,610
557,760
Mindreader Biotech retweeted
Keep your eyes on Climb Bio CLYM.Seems to have some smart money hanging around.
1
204
Mindreader Biotech retweeted
🚨 Fmr. FDA Commissioner David Kessler: “Over the last 40 years, the U.S. has been exposed to something that our biology was never intended to handle … Ultra-processed foods have altered our metabolism”
27
304
11
1,664
53,848
Mindreader Biotech retweeted
Well played, $CAPR . Publication in The Lancet to coincide with the AdCom. It should particularly appeal to the sciencey Committee members.
We're pleased to share that @TheLancet has published results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel in #Duchenne muscular dystrophy. The independent peer-reviewed publication validates the trial's design, statistical methodology and findings. HOPE-3 met its primary endpoint, with Deramiocel slowing upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and demonstrating a clinically meaningful cardiac benefit. Read more here: thelancet.com/journals/lance… We are grateful to the patients, families, investigators and study teams who made this research possible.
13
4
34
13,475
Today, Acting FDA Commissioner @FDA_KyleD & @HHSGov Senior Advisor @calleymeans had an eye-opening public discussion on the National Mall as part of @Freedom250 on regulatory changes focused on disease prevention. Among these, they emphasized school lunches, infant formula, & more transparency about healthier food choices. A cultural shift in what we eat back to real food (as we see in Europe and Asia), starting with early childhood, can have a transformative impact on our health.
6
22
1
92
3,639
Mindreader Biotech retweeted
Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release: bit.ly/4baOiNk
2
3
7
22
21,817
Mindreader Biotech retweeted
$IBRX - @ImmunityBio’s recurrent GBM data at @ASCO is impressive. In a disease where patients typically survive only 6-9 months after recurrence, their chemo-free combo (#ANKTIVA + PD-L1 t-haNK + Avastin) has 19 of 23 patients still alive after ~6 months median follow-up. Even better: they're seeing lymphocyte recovery instead of the usual destruction from chemo/radiation. Plus one complete response! The world needs to wake up to the power of #ANKTIVA. Abstract: meetings.asco.org/abstracts-…
🤖 Made with AI
3
25
3
117
4,391
Mindreader Biotech retweeted
Also, from me... This week's Biotech Scorecard newsletter: ‘No drama’ Kyle Diamantas should serve biotech well as acting FDA chief “The guy radiates normal,” a biotech executive who met with Diamantas recently told me. “He wouldn’t be out of place in any professional context that involves serious people thinking openly and constructively about how to solve serious problems, which might be the highest compliment I can pay.” statnews.com/2026/05/14/fda-…
13
8
62
12,676
Mindreader Biotech retweeted
Global expansion. Unstoppable
82
152
34
1,116
99,567
Mindreader Biotech retweeted
I have invested in Dr. Patrick's firms since 2018. He is a genius. A family member had stage 4 cancer. The Chemo was killing her. We decided to abandon the Oncologist and follow the regimen of "How to starve Cancer." She is now in remission 5 years, tumor free. The success rate of Chemo is about 2.7%, the same as 60 years ago. It has killed millions of people. The FDA must approve Anktiva from Dr. Pat for ALL CANCERS. It is ridiculous to say that one cancer is totally different than another. The problem is that the P53 gene that kills cancer is deactivated by cancer. Anktiva "reactivates" the P53 gene. The IL-15 is instrumental.
🔥 CANCER SCAM EXPOSED: Dr. Patrick Soon-Shiong Drops Bombshell — “Chemo Destroys the Very Cells That Could Save You” [VIDEO] 🔥 Exposed: Chemotherapy and radiation destroy your body’s natural killer cells — the immune warriors that could cure cancer. Dr. Patrick Soon-Shiong reveals “Bio-Shield Therapy,” a single injection keeping patients cancer-free for 10+ years. Biden’s FDA blocked it. Big Pharma tried to bury it. The future of medicine is here. 🔥 THE CANCER SCAM EXPOSED 👉 FULL STORY HERE: amg-news.com/cancer-scam-exp… 📢 Join our Telegram channel: t.me/AMGNEWS2022 🌐 Real stories. True journalism. Together, we make an impact: amg-news.com
11
146
3
581
31,448
Mindreader Biotech retweeted
Letting $repl resubmit was a farce. FDA put in place a review team instructed to reject RP1. Then they simply waited 6 months to issue the CRL.
2
1
1
26
3,616
Mindreader Biotech retweeted
America is failing in leading the way while the rest of the world embraces American technology and NK cell therapies! #ANKTIVA @DrMakaryFDA @POTUS
A thousand patients a day ! An international center dedicated to the integrated next generation immunotherapy treatment of cancer in Portugal. Never seen anything like this. Full commitment from an amazing medical/ surgical leadership and the Health Ministry and government !
6
33
188
4,227
Mindreader Biotech retweeted
$IBRX Warning Letter. 21% stock crash. $2 billion wiped out. Five class action lawsuits. Today, ImmunityBio filed an 8-K with the SEC. Inside it: a single number that ends every bear case in one line. The first quarterly results since the Warning Letter dropped. The first hard data on whether the regulatory chaos damaged the actual business. THE NUMBER Q1 2026 net product revenue: $44.2 million. That is the highest quarterly revenue in ImmunityBio's history. Up 168% from Q1 2025. Up 15% sequentially from Q4 2025. And every dollar of it was earned in the same three months that contained the Warning Letter, the lawsuit filings, and the stock decline. The unjustified complaints argue investors were misled about commercial prospects. The numbers tell a different story. The drug is real. The Warning Letter was noise. THE QUARTERLY TRAJECTORY This is what the curve looks like: - Q1 2025: ~$16.5 million (back-calculated from the 168% YoY figure) - Q2 2025: ~$23 million (estimated from full-year data) - Q3 2025: ~$35 million (estimated from full-year data) - Q4 2025: $38.3 million - Q1 2026: $44.2 million (15% sequential growth) Five quarters. Revenue nearly tripled. No deceleration. No flat quarters. No misses. Now consider what happened in Q1 2026 alone: - Insurance deductibles reset on January 1 - the structural headwind that hits every pharma in Q1 - The FDA Warning Letter on March 13 - Five class action lawsuits filed - A 21% stock crash on March 24 - Two weeks of bear-narrative media saturation Through all of that, ANKTIVA grew 15% sequentially. That is not a drug in trouble. That is a drug with organic gravity. UNIT GROWTH = NO DISCOUNTING Buried in the 8-K is one line that should make every bear retire: "ANKTIVA Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025." Unit growth matched dollar growth. That means: - No price cuts - No discounting to drive volume - No buy-one-get-one promotions - No channel stuffing Pure organic adoption. 168% more vials shipped at the same price per vial. This is what healthy commercial momentum looks like. When a drug starts losing momentum, units grow faster than dollars (because pricing falls). When a drug accelerates, units and dollars grow together. ANKTIVA's units and dollars are perfectly aligned. NCCN: THE MARCH CATALYST NOW SHOWING UP IN THE NUMBERS In today's 8-K, ImmunityBio confirms: "NCCN Clinical Practice Guidelines updated in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease (Category 2A)" This is not new news. NCCN added ANKTIVA in mid-March 2026 and the implications were discussed at the time. What is new is seeing it surface in an earnings filing as one of the company's own headline accomplishments for the quarter. NCCN guidelines are the gold-standard decision tree US oncologists use to decide what to prescribe. Category 2A means "uniform NCCN consensus that the intervention is appropriate." When a drug enters NCCN, payor coverage expands, hospital pathways get updated, and default prescribing kicks in. The NCCN inclusion happened in mid-March. It contributed to the back half of Q1 only. The full benefit ramps over Q2, Q3, Q4 as payors and hospital systems finish updating their pathways. The 168% YoY growth was generated with only two weeks of NCCN tailwind. The rest is still ahead. PSS also confirmed in the 8-K what was already public earlier this year: the BCG-unresponsive papillary disease sBLA has been resubmitted (after the May 2025 Refusal to File and subsequent agency discussions), and the BCG-naive sBLA based on QUILT-2.005 is "on track for 2026." Two pipeline catalysts, both already in motion before today's filing. Today's 8-K simply ties them into the commercial story. 240 MILLION LIVES COVERED In its full year 2025 reporting, ImmunityBio disclosed that ANKTIVA payor coverage now exceeds 240 million lives in the US, supported by a permanent CMS J-code (J9028) for the drug. This is the foundation that the Q1 2026 numbers are built on. 240 million lives is approximately 70% of the entire US insured population. Going from FDA approval (April 2024) to 240 million lives covered by year-end 2025 is roughly 20 months. That is exceptional payor uptake for a newly launched specialty oncology product. This is why the Warning Letter narrative was always going to fail. You cannot un-cover 240 million lives with a press release. The drug is in the formularies. The doctors are prescribing it. The patients are getting it. THE NUMBERS THAT KILL THE LAWSUITS THAT WERE ALREADY WEAK The lawsuits were built on shaky ground from the start. They are predatory securities class actions filed by firms (Hagens Berman, Pomerantz, Kirby McInerney, Kahn Swick & Foti, Kessler Topaz) that file the moment any biotech drops 20% on regulatory news. It is a business model, not a pursuit of justice. The goal is to recruit a lead plaintiff, survive a motion to dismiss, and settle for nuisance value. Most filings get dismissed or settled for pennies on the dollar. But here is the bigger problem with these specific lawsuits. They are built on the FDA Warning Letter. And the FDA Warning Letter has a fundamental factual problem. When ImmunityBio filed its formal response on April 6, the company informed the FDA that the television advertisement cited in the Warning Letter was NEVER AIRED. Never broadcast. Never disseminated to the public. The FDA issued a formal Warning Letter that crashed a stock and triggered class action lawsuits partly about content that never reached a single patient. One of the two pillars of the FDA complaint was about a phantom. The other pillar (a podcast) was real, and ImmunityBio removed it. But the founder's characterization of IL-15 as "highly promising" was based on the National Cancer Institute's own 2007 assessment that ranked IL-15 as the #1 immunotherapy molecule of 124 candidates. The company was being criticized for repeating what the government's own scientists had said first. So the lawsuit chain looks like this: a Warning Letter built partly on a phantom ad and partly on claims that match the NCI's own ranking → a stock crash that triggered automatic class action filings → securities fraud claims alleging investors were misled about commercial prospects. Now add Q1 2026: 1. Revenue of $44.2 million, the highest in company history, up 168% YoY 2. Unit volume up 168% (no discounting) 3. Sequential growth of 15% through the Warning Letter period 4. NCCN inclusion in March 2026 (during the class period) 5. 240 million lives covered (during the class period) 6. Cash position of $381 million There are no commercial prospects to mislead anyone about. The prospects are demonstrably stronger than they were before the Warning Letter. The lawsuits were always weak. They were built on a phantom TV ad and challenges to claims that the government itself first endorsed in 2007. Today's 8-K just made an already-weak case unwinnable. THE CASH POSITION DESTROYS THE BEAR THESIS A common 2025 bear concern: ImmunityBio's cash runway was tight relative to ongoing R&D and commercial spend. The post-Q1 reality: $380.9 million in cash and marketable securities at March 31, 2026. What changed: - $75 million non-dilutive Oberland royalty financing closed March 31 - $25 million Nant Capital debt-to-equity conversion (PSS taking dilution on himself) - Accelerating quarterly revenue ($44.2 million in Q1 alone) reduces the net burn Revenue is GROWING fast. With operating costs scaling much slower than revenue, operating leverage is kicking in. The path to cash flow neutrality is shortening with every quarter. If revenue continues at the current trajectory (and NCCN is a tailwind that is still ahead), 2026 full-year revenue could plausibly land between $200 million and $250 million. That is nearly DOUBLE 2025's $113 million. WHAT IS NOT IN THE 8-K The omissions are deliberate. Not mentioned: - The FDA Warning Letter - The class action lawsuits - The Champalimaud / Europe campaign - The sepsis Phase 3 trial (starts April 15) - The UCLA / Mount Sinai long COVID data (AACR this month) - The Saudi Arabia operational launch - The Würth Centre visit The 8-K is laser-focused on commercial execution and the bladder cancer pipeline. The message is: forget the international stories, forget the regulatory noise, forget the lawsuits. Look at the drug selling. Look at the trial enrolling. Look at the cash. This is corporate discipline. PSS is doing the international and pipeline narrative on Twitter. Richard Adcock, the CEO, is doing the commercial execution narrative through SEC filings. Two voices. One strategy. The same drug. THE TWO VOICES Adcock in the 8-K: "ANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution. Following strong growth in 2025, we are focused on scaling in the U.S. and expanding across an increasing number of global markets." CEO language. Adoption, execution, scaling, markets. Wall Street vocabulary. PSS in the same 8-K: "The sustained momentum of ANKTIVA reflects its growing commercial adoption in the BCG-unresponsive NMIBC CIS setting and feedback from treating urologists has been consistently positive. Across our clinical programs, we are seeing strong enrollment and growing investigator participation, supporting advancement of our broader pipeline. Full enrollment of our pivotal BCG-naïve CIS with or without papillary disease trial, with IDMC confirmation of adequate statistical power, further strengthens the expanding body of clinical evidence supporting ANKTIVA in the NMIBC bladder cancer setting. With our BCG-unresponsive NMIBC with papillary-only disease supplemental BLA now filed... we remain focused on advancing new treatment options for patients with bladder cancer and other indications." Founder language. Treating urologists, clinical programs, investigator participation, sBLAs in motion. Doctor vocabulary. Same numbers. Two audiences. The CEO talks to analysts. The founder talks to physicians. Both quotes appear in the same SEC filing because both groups need to hear the same message in their own language. THE 2007 PROPHECY IS BEING FULFILLED IN PRINT On July 12, 2007, the National Cancer Institute convened the Immunotherapy Agent Workshop. Top scientists from NCI, NIH, FDA, AACR and ASH ranked the 124 immunotherapy agents most likely to cure cancer. IL-15 came out at #1. In the manuscript, the workshop wrote its own self-test: "if a year or two goes by and the list remains substantially unchanged, it would be a signal that the current system for developing immunotherapeutic agents is not working optimally." Seventeen years passed. The molecule was never built. Until one man built it. Today, that molecule generated $44.2 million in a single quarter. 168% YoY growth. NCCN inclusion. 240 million lives covered. $381 million in cash. A trial fully enrolled with statistical power confirmed. The 2007 workshop predicted what would happen. It just took the right person to make it happen. And the financial statements now confirm it. The molecule the establishment ranked #1 nineteen years ago is the highest-revenue product in this company today. And it is accelerating, not slowing. NINE DAYS Look at what is happening right now: April 6: ImmunityBio files FDA Warning Letter response, citing the 2007 NCI workshop as the basis for PSS's IL-15 claims April 7: PSS posts about UCLA + Mount Sinai data on COVID-induced lymphopenia driving cancer recurrence April 8: PSS visits Champalimaud Foundation in Lisbon with the Portuguese Health Minister at the same foundation April 9: PSS confirms "1,000 patients a day" and "full commitment from the Health Ministry and government" April 9: Q1 2026 earnings 8-K - record revenue, 168% YoY, NCCN inclusion, $381M cash April 10: Islamabad peace talks begin between US and Iran (ceasefire announced April 7, Hormuz reopening) April 15: Sepsis Phase 3 trial starts in the US (separate from the bladder cancer trials in the 8-K - this is the sepsis indication, NCT07492875) Nine days. Seven catalysts. One company. THE BEARS HAVE NOTHING LEFT The Warning Letter narrative is dead. The numbers killed it. The cash runway narrative is dead. The financing killed it. The pricing power narrative is dead. The 168% unit growth killed it. The international expansion question mark is dead. The Health Minister killed it. The pipeline timing question is dead. QUILT-2.005 hit IDMC confirmation and the papillary sBLA was resubmitted. What is left? The lawsuits. And the lawsuits were already weak - built on a Warning Letter that cited a TV ad that never aired and challenged claims that the NCI itself first published in 2007. The Q1 2026 8-K just turned an already-weak case into an unwinnable one. ImmunityBio's response to the FDA Warning Letter (filed three days ago, citing the NCI's own 2007 ranking as the basis for its IL-15 claims) was the legal defense. Today's 8-K is the commercial defense. Both came from the same week. The 2007 workshop predicted that the institutional system would fail to deliver the most important molecule in immunotherapy. The system did fail. One man and his team built it anyway. Today, that drug grew 168% year-over-year while the system was attacking it. The numbers do not care about Warning Letters. The numbers do not care about lawsuits. The numbers do not care about media narratives. The numbers care about patients getting treated. And in Q1 2026, more patients got treated with ANKTIVA than in any quarter in history. This is what the prophecy looks like when it stops being a story and starts being a financial statement.
13
25
3
165
8,946
Mindreader Biotech retweeted
$IBRX has fallen from $12 to below $8 a share. But, I could still see it explode to over $20 a share within the next year… The underlying fundamentals are completely decoupled from the recent price action. Prelim 2025 revenue hit $113M (a +700% YoY increase), with Q4 unit sales up +750%. ANKTIVA is now authorized in 33 countries, backed by a massive new EU rollout partnership. Wall Street still prices this strictly as a bladder cancer play, completely ignoring recent approvals for metastatic Lung Cancer (NSCLC) in Saudi Arabia. This cracks open a multi-billion dollar TAM. The California Bio-Plant, a 100,000 sq ft state of the art GMP facility housing large-scale bioreactors. Once fully operational, this plant alone will have the capacity to produce the raw drug substance for 1 million doses of ANKTIVA annually. The Dunkirk Behemoth - To handle the final production stages, $IBRX secured a massive 400,000 sq ft facility in Dunkirk, NY. Dedicated to fill and finish. This plant is designed to pump out 1 million vials a year, ensuring they never face supply chain bottlenecks as global demand scales With top analyst targets sitting at $25.20, commercial execution is accelerating while the stock lags. @DrPatrick wrote the book of a successful commercial rollout, $IBRX is firing on all cylinders and executing a an unusually high level for a Bio-tech company.
9
12
87
3,795
Mindreader Biotech retweeted
Will submit data..coming soon. NCI, NIH and even FDA knew since 2007 that IL15 was a game changer for cancer of all types. Every scientific thought leader ranked it number one ..almost 20 years ago. I hope Marty sits down with the reviewers when the data comes in. Saving patients bladders matter. Prolonging life matters. Quality of life matters. T cell and NK cell expansion matters. Duration matters.
FDA Commissioner Dr. Marty Makary revealed a major shift at the agency that’s still making waves: “I personally meet one-on-one with reviewers and ask: ‘Are you seeing anything that gives you chills up your spine because it could be such a game-changer?’” He described the FDA’s new proactive approach: - No more passive waiting for applications. - When early data looks “too good to be true,” they call companies directly: “Forget the paperwork — send more data now.” - Fast-track vouchers for decisions in weeks instead of years. - Recent example: gene therapy restored normal hearing in 3 of 12 deaf children (improved in 7) with perfect safety — FDA contacted the company days after NEJM publication. Makary emphasized the FDA is aggressively tracking promising treatments for blindness, deafness, pediatric/rare diseases, cancers — and a “potentially promising” therapy for type 1 diabetes that has reviewers excited. This is the FDA acting like it’s on the front lines of curing disease, not just regulating it. Months later — are you hopeful this new mindset finally delivers real cures, or waiting to see hard results?
55
226
25
1,096
84,782
Mindreader Biotech retweeted
$IBRX 🚨 The interview with @DrPatrick and Bret Baier on #cancer treatment („Search for a Cure“) just aired on Fox News. Immunity Bio’s Mission is getting more attention, which is great. Exciting conversation, nice animations. 👇🏻
14
115
11
594
39,708